國家衛生研究院 NHRI:Item 3990099045/6138
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12145/12927 (94%)
造訪人次 : 925156      線上人數 : 906
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/6138


    題名: A phase II study of neoadjuvant bio-chemotherapy with Cetuximab, Paclitaxel, and Cisplatin (CPC) followed by Cetuximab-based concurrent bio-radiotherapy in high-risk locally advanced head and neck cancer - representative of head and neck cancer study grou
    作者: Chang, KY;Yen, CJ;Hsieh, CY;Tsou, HH;Chiu, CF;Chen, CC;Tsao, CJ;Tsai, KY;Tsai, ST;Chang, JY
    貢獻者: National Institute of Cancer Research;Division of Biostatistics and Bioinformatics
    摘要: Background: To evaluate the therapeutic efficacy of sequential regimen using cetuximab-based triplet neoadjuvant chemotherapy (NC) followed by concurrent bio-radiotherapy (BRT) in locally advanced head and neck cancer (HNC) patients. Materials and Methods: Eligible criteria included treatment-na??ve patients with histologically confirmed squamous cell carcinoma originated from oral cavity or oropharyngeal area, and the disease staging beyond N2b or T4. The CPC regimen for NC consisted of cetuximab 500 mg/m2, paclitaxel 120 mg/m2, cisplatin 50 mg/m2, every two weeks for five courses. Patients without disease progression would receive cetuximab 500 mg/m2 every two weeks concurrently with radiotherapy for total dose of 70 Gy. Results: Since October 2009 to November 2010, 47 patients were recruited to the study. Of all patients, 93.6% had N2b, N2c or N3 disease. The mean age of the patients was 50.4 years old, and the Eastern Cooperative Oncology Group performance status 0 and 1 was in 31.9% and 68.1%, respectively. The primary lesion was located at oral cavity in 57.4%, and at oropharyngeal area in 42.6% of patients. On intentionto-treat analysis (ITT), the best overall response was partial response (PR) in 30 patients, complete response (CR) in 3, stable disease (SD) in 12. The overall response rate was 70.2%. The best response rate after NC was 48.9%, including PR in 22 and CR in 1. Two patients had progressive disease (PD) before BRT, and among the other 45 patients, two declined to have radiotherapy. Of the 43 patients receiving BRT, two patients discontinued treatment due to treatment-unrelated complication or suggestion of surgical intervention. In the remaining 41 patients, additional 10 and 2 patients achieved PR and CR, respectively. In addition, seven developed PD, and two were not evaluable due to early termination as a consequence of toxicity. The most common grade 3 or 4 adverse events in the NC were neutropenia, while mucositis, anorexia, and dermatitis accounted for the major complications during the BRT. Conclusions: The cetuximab-based sequential regimen showed to be efficient in high-risk locally advanced HNC. CPC regimen was feasible in most patients. However, adequate supportive care is necessary for the toxicity during the period of cetuximab-based radiotherapy.
    日期: 2011-09-23
    關聯: European Journal of Cancer. 2011 Sep 23;47:S547-S548.
    Link to: http://dx.doi.org/10.1016/S0959-8049(11)72155-4
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0959-8049&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000295752801881
    顯示於類別:[張光裕] 會議論文/會議摘要
    [鄒小蕙] 會議論文/會議摘要
    [張俊彥] 會議論文/會議摘要

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    ISI000295752801881.pdf58KbAdobe PDF683檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋